Imbioray is a clinical-stage innovative biopharmaceutical company, the pioneer of generic off-the-shelf trained-immunity NK cells, dedicated to the research, development, and clinical application in the cell field. It has achieved comprehensive applications of ACC-NK (antibody-cell conjugate NK), ATE-NK (antibody-targeted enhanced NK), and tiNK (trained-immunity NK) in solid and hematological tumors, various non-oncological diseases, and health management.
Imbioray owns cutting-edge patented technology for NK cell immunity training and a world-class large-scale GMP production center. It is an industry standard-setter for the entire chain of NK cell preparation—from raw material collection to release and clinical application. With its high technology, efficiency, and quality, it has become a representative enterprise of national "New Quality Productive Forces."
View More
Dedicated to NK Cell Research
R&D Talents
Honors at Home and Abroad
IND & Biomedical New Technologies
Number and Progress of Clinical Trial Projects
Product Service
ACC-NK (Antibody-cell Conjugate NK) integrates the antigen-targeting function of antibodies and the immune killing function of NK cells through antibody conjugation technology (non-viral vector, non-gene editing). By targeting specific tumor antigens with antibodies, it can quickly and efficiently guide NK cells to recognize and kill tumor cells.
Product Service
ATE-NK (Antibody Targeted Enhanced NK), which stands for antibody-targeted enhanced NK cells, involves the combination of specific antibodies and NK cells to precisely target and eliminate pathologically reactive B/T lymphocytes. Leveraging the "precise navigation" capability of antibodies, it guides NK cells to efficiently exert their cytotoxic effects. Through antibody-dependent cellular cytotoxicity (ADCC), it enhances the killing efficiency of NK cells, achieving the dual efficacy of "targeted clearance + immune regulation". It is expected to become a breakthrough therapy for autoimmune diseases.
Product Service
tiNK® (trained immunity NK) immune-trained NK cells refer to NK cells activated and immunologically trained through specific factors. Training is a cultivation method that simulates the stress conditions faced by NK cells. By utilizing high-intensity cytokines, the killing ability of NK cells is enhanced, just like training a "new recruit of special forces" into a "king of special forces", enabling them to more quickly and effectively eliminate bacteria, viruses, senescent cells, and mutated cells in the human body.
Latest News
银屑病，俗称“牛皮癣”，因为名称中带了一个“癣”字，很多人误以为“牛皮癣”是如足癣（脚气）、体癣等由真菌感染引起，并具有传染性的皮肤病。但事实上，它是一种与免疫紊乱密切相关的系统性、慢性、炎症性皮肤病，虽然常表现为局部或广泛分布的鳞屑性红斑或斑块，但银屑病不具传染性。根据世界卫生组织统计，全球约有1
Learn More2026年6月10日，英百瑞自主研发的核心产品ACC-NK（IBR854）细胞注射液，联合多西他赛用于一线标准治疗失败的晚期非小细胞肺癌患者的二线治疗的Ⅱ期临床试验，正式获得国家药品监督管理局临床默示许可，获批进入Ⅱ期临床试验。（通知书编号：2026LP01773、2026LP01774）这是继20
Learn More2026年6月8日，细胞治疗赛道再次迎来英百瑞的临床突破！英百瑞ACC-NK（IBR822）细胞注射液联合多西他赛用于一线标准治疗失败的晚期非小细胞肺癌患者的二线治疗II期临床试验项目正式获得国家药品监督管理局药品评审中心受理！（受理号:CXSL2600612、CXSL2600613）这标志着英百瑞
Learn More2026年6月6日，英百瑞（杭州）生物医药股份有限公司董事长苗振伟，英百瑞医学研究中心创始人赵晨、熊苏城，陕西中心总经理安慧子及核心管理团队，受邀出席宝鸡市中心医院举办的陕西省区域医疗中心暨宝鸡市中心医院高质量发展大会。会上，英百瑞董事长苗振伟博士代表公司与宝鸡市中心医院正式签署战略合作协议，双方将
Learn More
Scan the QR code to learn more
Consultation Hotline400-995-9976
Copyright2025 英百瑞（杭州）医学研究有限公司 All Rights Reserved. 浙ICP备2025205905号 DESIGN BY : WEETOP
